The inaugural workshop explored skin cancer care from prevention and diagnosis through systemic therapy, radiation, and multidisciplinary management.
|Podcasts|November 19, 2020
The Cutaneous Connection- Episode 11: Racial Disparities in Melanoma Awareness
Author(s)Morgan Petronelli
Neelam Vashi, M.D., FAAD, discusses the publication of her cross-sectional survey in the Journal of the American Academy of Dermatology regarding how different racial and ethnic groups possess various levels of melanoma awareness.
Advertisement
Advertisement
Related to this article
The final session of the Cutaneous Oncology Workshop explored advances in systemic therapy, management of immunotherapy-related skin reactions, and the role of radiation.
At the Dermatology Times NP/PA Cutaneous Oncology Workshop in Tampa, Florida, Amit Om, MD, outlined why field-directed therapy is increasingly favored over lesion-directed treatment for actinic keratosis.
Faculty at the Dermatology Times Cutaneous Oncology Workshop addressed real-world questions on mole mapping, biopsy decisions, oral photoprotection, and actinic keratosis treatment.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.
At the Cutaneous Oncology Workshop, faculty explored lesion recognition, surgical decision-making, risk stratification, and the evolving role of molecular testing.
In the morning session, Experts highlighted evolving photoprotection strategies, field-directed treatment of actinic keratoses, hereditary cancer risk, and practical dermoscopy pearls for APPs.
Advertisement
Advertisement
Trending on Dermatology Times
1
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
2
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
3
FDA Grants Priority Review to Zasocitinib for Moderate-to-Severe Plaque Psoriasis
4
FDA Accepts Bezuclastinib NDA for Advanced Systemic Mastocytosis
5